A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging

Author(s): Xia Lu, Rong Fu Wang.

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 8 , 2012

Become EABM
Become Reviewer

Abstract:

Angiogenesis is necessary for tumor growth, without which a tumor can not grow beyond a few millimeters in diameter. This review summarizes the current status on the research of peptide Arg-Gly-Asp (RGD) and Arg-Arg-Leu (RRL) as well as its derivatives applied in tumor angiogenesis imaging and targeted therapy with single photon emission tomography (SPECT) and positron emissiontomography (PET). Peptide RGD sequence Arg-Gly-Asp targeted and combined to integrin αvβ3 which has been overexpressed on tumor endothelial cells and many different tumor cellsis a robust site for tumor angiogenesis molecular imaging and targeted therapy. The vari-ous derivatives of RGD were focused on optimizing its biological characteristics including affinity, targeting efficacy and pharmacoki-netics. The other alternative novel tumor angiogenesis molecular imaging agent is RRL peptide which targeted to tumor derived endothe-lial cells and then applied to visualize tumor angiogenesis with enhanced ultrasonic imaging, optical imaging and SPECT in animal. These novel peptide agents can have promising applications for tumor angiogenesis imaging and antiangiogenic tumor therapy.

Keywords: Tumor angiogenesis, Vascular endothelial growth factor, Vascular endothelial growth factor receptor, Integrin αvβ3, Peptide RGD, Peptide RRL, Tumor molecular imaging, Targeted therapy, tumor growth, ultrasonic imaging

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 18
ISSUE: 8
Year: 2012
Page: [1032 - 1040]
Pages: 9
DOI: 10.2174/138161212799315812
Price: $58

Article Metrics

PDF: 8